Johnson & Johnson has received FDA approval for its Ottava soft tissue surgical robot. This development has led to a decline in the stock of competitors like Intuitive Surgical and Medtronic.

This week's notable healthcare headlines highlight developments concerning major industry players such as UnitedHealth, Johnson & Johnson, and Intuitive Surgical.

Intuitive Surgical (ISRG) stock experienced a decline after analysts revised down their price targets for the company.

Intuitive Surgical reaffirmed its 13.5%-15.5% da Vinci procedure growth outlook for 2026 and provided a non-GAAP gross margin range of 68%-69%.

Intuitive Surgical announced strong second-quarter earnings, with revenue jumping 19% year-over-year, exceeding expectations due to high demand for its da Vinci surgical systems.

Intuitive Surgical is projected to have over 35% upside, presenting a compelling buy opportunity before July 16, according to market analysis.

This article presents a prediction and analysis supporting the forecast that Intuitive Surgical will achieve a market valuation of $500 billion by the year 2031.

An analysis assesses if Intuitive Surgical (ISRG) is the optimal large-cap stock to invest in while it trades at its 52-week lows.

Despite a significant increase of over 400% in its stock price, Intuitive Surgical is still considered a compelling investment opportunity.

Jim Cramer provided varied investment advice on several companies, expressing skepticism about stocks like McGraw Hill, Boston Scientific, and Rivian, while recommending Madison Square Garden Sports and maintaining a positive outlook on SoFi.

Intuitive Surgical (ISRG) has announced the promotion of Taylor Patton to the position of Chief Commercial and Marketing Officer.

Following a significant decline in 2026, an analysis explores whether now is an opportune time to invest in Intuitive Surgical stock.

Intuitive Surgical (ISRG) is preparing to implement nearly 100 upgrades to its da Vinci 5 robot, with the rollout scheduled to commence in June.

Wall Street analysts are reportedly assessing the investment outlook for Intuitive Surgical stock, with discussions focusing on its potential performance.

An analysis suggests that Intuitive Surgical's competitive moat is strengthening, leading to speculation about its potential as a long-term 'forever' stock.

Financial analysts are evaluating whether Medpace Holdings, Inc. (MEDP) and Intuitive Surgical, Inc. (ISRG) are good investment opportunities. These articles provide insights into the current stock performance and future prospects of the companies.

Shareholders of Intuitive Surgical approved all proposals and elected 10 directors at the company's 2026 Annual Meeting.

Intuitive Surgical's stock experienced a significant surge, drawing attention to exchange-traded funds with high exposure to the company. This rise also coincided with a notable increase in Beyond Meat's stock.

Intuitive Surgical, Inc. has released its summary for the first quarter of 2026 earnings call. The report details the company's financial performance and key highlights from the period.

BITG has lowered its price target for Intuitive Surgical, Inc. (ISRG) shares, attributing the change to the anticipated impact of the CMS FY27 payment rule.

Intuitive Surgical stock is being highlighted as a significant contender in the rapidly expanding anti-obesity market, suggesting its potential for growth and impact in this sector.

Intuitive Surgical, Inc. (ISRG) has reportedly maintained its competitive market position even after experiencing a security breach.

Further analysis highlights Intuitive Surgical's position as a clear leader in the field of robotic-assisted surgery, examining factors contributing to its prominence and sustained market leadership.

Intuitive Surgical experienced a decline in its stock value following the announcement of a cybersecurity incident affecting the company.

Intuitive Surgical, Inc. has announced the successful completion of its acquisition of the da Vinci and Ion Distribution Business.

A report highlights Intuitive Surgical, a leader in robotic surgery, as a company with strong potential for continued growth and market compounding over the next decade.

Intuitive Surgical (ISRG) experienced a decline in stock price despite possessing strong fundamental indicators.

Intuitive Surgical and CoreWeave stocks both experienced drops this week. The reasons for their respective declines were highlighted in various reports.

Intuitive Surgical's stock experienced a decline as renewed concerns over Obamacare rekindled debates about demand in the medtech sector.

Intuitive Surgical's stock has dropped as changes to the Affordable Care Act (ACA) and the impact of GLP-1 drugs weigh on the company's growth prospects.

BMO Capital has started coverage of Intuitive Surgical (ISRG) with an Outperform rating.

An analysis explores whether Intuitive Surgical (ISRG) stands out as one of the best artificial intelligence (AI) stocks to consider buying within the MedTech sector.

Intuitive Surgical's stock has fallen 28%, but Goldman Sachs maintains a bullish outlook, asserting that the market's current assessment is incorrect and historical trends support their position.

An analysis compares Stryker's competitive advantage in the joint-replacement market against Intuitive Surgical's high valuation. The report delves into the respective market positions and financial outlooks of the two medical technology companies.

Piper Sandler has highlighted Intuitive Surgical (ISRG) due to its long-term growth catalysts, suggesting a positive outlook for the company.

Intuitive Surgical (ISRG) is being considered as a potential hedge against market risk.

An analysis provides a perspective on whether Intuitive Surgical, Inc. (ISRG) is a good stock to purchase.

An article examines whether Intuitive Surgical (ISRG) stock is underperforming relative to the broader healthcare sector.

Intuitive Surgical (ISRG) has announced several new innovations designed to advance its 'Quintuple Aim' objectives, likely related to improving patient outcomes and healthcare efficiency.

Intuitive Surgical's stock has fallen 20% this year, but Wall Street analysts are now advising investors to buy.

An article identifies an under-the-radar healthcare stock, suggesting it could be a better long-term investment than Intuitive Surgical. The analysis recommends buying and holding this particular stock indefinitely.

Jim Cramer provided his latest insights on a diverse portfolio of stocks, commenting on companies like Oklo, Reddit, Palantir, Meta, Microsoft, Amazon, Alphabet, Mastercard, Intuitive Surgical, Apple, Caterpillar, and Arm Holdings. He discussed their performance, market trends, and investment potential.

An analysis examines whether Intuitive Surgical's stock has further growth potential following its strong performance in the first quarter.

Intuitive Surgical reported first-quarter results that surpassed analyst estimates, driven by an accelerating demand for robotic surgery. The company's performance indicates strong growth in the robotic-assisted surgical market.

Key takeaways and financial performance details from Intuitive Surgical's first-quarter earnings call have been released.

Truist has reiterated its 'Buy' rating for Intuitive Surgical (ISRG), indicating continued confidence in the company's stock performance.

The aging population trend, dubbed the "Silver Tsunami," is expected to create significant opportunities, with Intuitive Surgical identified as a potential major beneficiary.

Analysts are providing expectations for Intuitive Surgical's first-quarter 2026 earnings report, anticipating key financial metrics and company performance.

Several stocks, including NVIDIA, Tesla, Intuitive Surgical, Deere, and Rockwell Automation, saw price changes following specific comments and recommendations from financial personality Jim Cramer, while others like Symbotic, UiPath, Ambarella, and SoundHound AI reacted negatively to his caution or criticism.

An analysis questions whether Intuitive Surgical Inc. (ISRG) is currently the best pure-play robotics stock for investors to consider.

An article analyzes whether Intuitive Surgical's stock is underperforming the Dow Jones Industrial Average.

Intuitive Surgical is being highlighted as a potentially resilient medtech stock that could withstand market downturns, suggesting its strong position in the healthcare sector.

Intuitive Surgical's stock is currently trading at multi-year lows, prompting analysis on whether it represents a bargain buying opportunity for investors.

Despite a strong quarterly performance, Intuitive Surgical's results reportedly spooked investors, prompting an analysis of the market reaction.

Intuitive Surgical's shares declined even after the company reported an earnings beat, as its 2026 outlook failed to impress investors.

Key highlights from Intuitive Surgical's second-quarter earnings call have been released, detailing the medical device company's financial results and operational updates.

Stock index futures are extending gains as investors anticipate upcoming earnings reports and wholesale inflation data. Companies like Intuitive Surgical are preparing to release their quarterly results.

An analysis explores the potential growth trajectory and future prospects for Intuitive Surgical stock in the market.

Intuitive Surgical (ISRG) stock experienced a decline after the company issued a forecast that fell below market consensus expectations.

Intuitive Surgical's competitive advantage is reportedly growing stronger, leading some to consider it a 'forever' stock due to its robust market position.

Deutsche Bank has reiterated its 'Sell' rating on Intuitive Surgical (ISRG), providing reasons for its continued bearish outlook on the company's stock.

Deutsche Bank reportedly remains unconvinced about the prospects of Intuitive Surgical (ISRG), according to a recent analysis.

An analysis explores whether Medtronic can effectively challenge Intuitive Surgical's long-standing dominance in the market for robotic surgical systems.

Goldman Sachs has reiterated its 'Buy' rating for Intuitive Surgical (ISRG), indicating continued confidence in the company's stock performance.

Intuitive Surgical (ISRG) and Zimmer Biomet Holdings (ZBH) are being evaluated as leading investment opportunities within the robotic surgery sector. Both companies are highlighted for their potential in this growing market.

Intuitive Surgical (ISRG) is highlighted as one of the best agentic AI stocks for current investment. The analysis suggests its strong position in the evolving artificial intelligence market.

According to analysts, Intuitive Surgical (ISRG) is considered the best healthcare AI stock to buy, highlighting its strong position in the market.

An analysis suggests that Intuitive Surgical's continued success is due to a highly profitable aspect of its business model, described as a 'cash machine hiding in plain sight.'

Intuitive Surgical has announced another quarter of robust financial results, leading to speculation about the company's stock performance.

The earnings transcript for Intuitive Surgical (ISRG) for the third quarter of 2024 has been released, detailing the company's financial performance.

Mizuho, BTIG, and Evercore have all lowered their price targets for Intuitive Surgical (ISRG), indicating a revised outlook for the medical device company.

Intuitive Surgical's stock is up 2.7% in anticipation of its earnings report, leading to questions about whether the robotics company is set for a recovery.

Intuitive Surgical (ISRG) is reportedly improving surgical precision through the integration of artificial intelligence, marking a significant advancement in medical technology.

A financial article provides an analysis on whether Intuitive Surgical, a medical technology company, is currently a good investment.

This article provides an analysis on whether Intuitive Surgical, Inc. (ISRG) is currently a favorable stock to purchase. It likely delves into financial metrics and market performance to assess its investment potential.

Analysts express strong confidence in Intuitive Surgical (ISRG) as the company continues its efforts to expand its market footprint.

Intuitive Surgical received an upgrade to 'Buy' from Citi, while analysts also made key moves on Stryker and Abbott, signaling shifts in investment recommendations for medical technology companies.

Intuitive Surgical, Inc. (ISRG) is experiencing optimism driven by its new Da Vinci 5 product.

Wall Street analysts Tom Lee and Dan Ives offer conflicting views on the software market, with one advising to 'buy' and the other predicting 'layoffs are coming'.